Rockwell Automation and Comau Partner to Simplify Robot Integration for Manufacturers
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, and Comau, a global leader in industrial automation and robot manufacturer, announced today that they are joining forces to give businesses worldwide vital tools to maximize manufacturing efficiencies through unified robot control solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005326/en/
Comau Rebel-S (Photo: Business Wire)
“Industrial companies are looking for efficient ways to integrate robotics into their operations for process optimization and agility,” said Rockwell Automation Chairman and CEO Blake Moret. “Rockwell Automation’s collaboration with Comau will simplify programming and lifecycle management, accelerating time to value for our customers.”
Moret said this expansion of robotic applications is rooted in Rockwell’s broader strategy to help industrial companies save time and improve performance with unified robot control, ultimately providing long-term value for their business. The partnership is a collaborative development and selling model that offers the unified robot control product to both companies’ customers.
“Comau’s robotics and industrial automation expertise, as well as its reputation for high performance, reliability, and quality, combined with Rockwell Automation’s global capabilities and experience in automated material handling, food and beverage, household and personal care, and life sciences, gives customers the incremental value of an integrated robot solution,” said Comau CEO Paolo Carmassi. “Comau is eager to work with such an important partner that has a market-leading global footprint in all industries.”
Engineers will now be able to program their entire machine in one environment, including Comau robot arms directly controlled through Rockwell Automation’s Logix-based controllers. Rockwell Automation’s Studio 5000® automation system design software provides relief from the time-consuming and often difficult task of trying to coordinate traditionally separate machine control and robot systems to work together using two different software tools.
Machine builders, system integrators, and others will gain development and deployment efficiencies through the use of digital engineering tools like Rockwell’s Emulate3D digital twin software, which creates digital models of production lines, auto-generates machine control code, and has built-in capabilities for Comau robots.
The combined Rockwell and Comau solutions will also offer benefits beyond enhanced integration. For example, end users can use analytics and digital twin tools to gain deeper insights into machine performance and potential production optimization. They can also use safety and security solutions to reduce business risks.
Operators on the manufacturing floor who use Rockwell’s FactoryTalk® software suite will benefit from being able to see both line and robot control systems on a single interface. In-plant and remote technicians will only need to learn and maintain one architecture to monitor both systems. They can also leverage Rockwell’s augmented reality (AR) tools to improve lifecycle and service cycle maintenance.
Automazioni Industriali Capitanio, a recognized system integrator, designs, manufactures, and commissions automation systems for the metals industry and is an early adopter of the joint solution. Marco Capitanio, managing director of AIC, said the Rockwell-Comau collaboration allows the company to offer a seamless robot solution for customers, which he sees as a key advantage for a machine builder.
“We value the simple and flexible programming environment, complete access to robot supervision and diagnostic parameters, and the ability to leverage existing automation panels and standard control devices,” Capitanio said.
Rockwell products and technology that will be key to robotics integration include the following:
- Allen-Bradley ControlLogix® control systems
- Kinetix® 5700 servo drive platform
- Studio 5000® automation system design software
- FactoryTalk® View human machine interface (HMI) software
- FactoryTalk® InnovationSuite™, powered by PTC digital transformation software suite
- Emulate3D™ digital twin software
- PTC Vuforia AR tools for remote collaboration and information capture
Comau’s comprehensive robot range meets the needs of a wide variety of industries, from automotive to logistics, food and beverage, and packaging, just to name a few. It includes more than 40 different industrial robotic arms, with load capacities from 3 to 650 KG.
About Comau
Comau, a member of Stellantis, is a worldwide leader in delivering advanced industrial automation products, and systems. With over 45 years of experience and a strong presence within every major industrial country, Comau is helping manufacturers of all sizes in almost any industry experience higher quality, increased productivity, faster time-to-market, and lower overall costs. Headquartered in Turin, Italy, Comau has an international network of 7 innovation centers, 5 digital hubs, 8 manufacturing plants that span 14 countries and employ more than 9,000 people. For more information, visit www.comau.com.
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 23,500 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005326/en/
Contact information
Media contacts:
Marci Pelzer
Rockwell Automation - Americas
+1 414-382-5679
MPelzer@rockwellautomation.com
Stan Miller
Rockwell Automation - EMEA
+44 778 099 8582
samiller1@ra.rockwell.com
Giuseppe Costabile
Comau
+39 3387130885
giuseppe.costabile@comau.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom